Analysts expect that ContraFect Corporation (NASDAQ:CFRX) will report earnings of ($0.14) per share for the current quarter, Zacks reports. Zero analysts have made estimates for ContraFect Corporation’s earnings, with the highest EPS estimate coming in at ($0.10) and the lowest estimate coming in at ($0.18). ContraFect Corporation reported earnings per share of ($0.28) in the same quarter last year, which would indicate a positive year over year growth rate of 50%. The company is expected to report its next earnings report on Wednesday, November 8th.

According to Zacks, analysts expect that ContraFect Corporation will report full year earnings of ($0.55) per share for the current fiscal year, with EPS estimates ranging from ($0.68) to ($0.40). For the next fiscal year, analysts forecast that the company will report earnings of ($0.49) per share, with EPS estimates ranging from ($0.63) to ($0.34). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of analysts that cover ContraFect Corporation.

ContraFect Corporation (NASDAQ:CFRX) last announced its earnings results on Wednesday, August 9th. The biotechnology company reported ($0.07) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.11.

Separately, Maxim Group restated a “hold” rating on shares of ContraFect Corporation in a research note on Wednesday, April 19th.

ILLEGAL ACTIVITY NOTICE: This article was originally posted by Watch List News and is owned by of Watch List News. If you are viewing this article on another site, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The correct version of this article can be viewed at

Shares of ContraFect Corporation (NASDAQ:CFRX) traded down 2.04% during midday trading on Tuesday, reaching $1.20. 71,190 shares of the company were exchanged. ContraFect Corporation has a 12-month low of $1.10 and a 12-month high of $3.28. The stock’s market capitalization is $49.99 million. The company has a 50 day moving average price of $1.35 and a 200-day moving average price of $1.60.

In other news, Director Sol J. Barer acquired 40,000 shares of the firm’s stock in a transaction dated Tuesday, July 25th. The shares were acquired at an average cost of $1.24 per share, with a total value of $49,600.00. Following the acquisition, the director now directly owns 815,933 shares of the company’s stock, valued at $1,011,756.92. The transaction was disclosed in a document filed with the SEC, which is available at this link. Insiders have bought a total of 50,800 shares of company stock worth $62,992 over the last ninety days. Insiders own 9.30% of the company’s stock.

An institutional investor recently raised its position in ContraFect Corporation stock. White Pine Capital LLC boosted its stake in ContraFect Corporation (NASDAQ:CFRX) by 0.3% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 253,870 shares of the biotechnology company’s stock after buying an additional 825 shares during the period. White Pine Capital LLC owned approximately 0.61% of ContraFect Corporation worth $368,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 25.22% of the company’s stock.

Get a free copy of the Zacks research report on ContraFect Corporation (CFRX)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for ContraFect Corporation (NASDAQ:CFRX)

Receive News & Ratings for ContraFect Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraFect Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.